Assessed for eligibility (n = 1140)

Did not meet inclusion criteria (n = 748)
Refused to participate (n = 29)
Other (n = 78)

Randomized (n = 285)

Placebo (n = 99)
Received study dose (n = 98)

Lost to follow up (n = 1)
Adverse event (n = 12)
Noncompliance with protocol (n = 1)
Patient reconsidered/withdrew consent (n = 5)

Placebo completed (n = 80)

Risedronate 5 mg/d (n = 96)
Received study dose (n = 96)

Lost to follow up (n = 2)
Did not meet enrollment (n = 2)
Adverse event (n = 7)
Noncompliance with protocol (n = 2)
Patient reconsidered/withdrew consent (n = 3)

Risedronate 5 mg/d completed (n = 80)

Risedronate 15 mg/d (n = 90)
Received study dose (n = 90)

Lost to follow up (n = 1)
Adverse event (n = 10)
Noncompliance with protocol (n = 2)
Patient reconsidered/withdrew consent (n = 6)

Risedronate 15 mg/d completed (n = 71)

Did not meet inclusion criteria (n = 748)
Refused to participate (n = 29)
Other (n = 78)